MELDUNG VOM 07.09.2017 18:00
Meldung drucken Artikel weiterleiten
pta20170907034
Public disclosure of inside information according to article 17 MAR
Pressefach Pressefach

Medigene AG: Medigene announces issuance and number of new shares to settle last Trianta milestone payment

Planegg (pta034/07.09.2017/18:00) - The Executive Management Board of Medigene AG (FSE: MDG1, Prime Standard, TecDAX) with the approval of the Company's Supervisory Board today resolved, that the EUR 2 million milestone payment announced on 10 July 2017 for the achievement of the third milestone for the Trianta acquisition will be settled by issuance of new shares. These shares will be issued from authorized capital by means of a capital increase through contribution in kind. The share capital will be increased from EUR 22,118,612.00 to EUR 22,300,947.00 through the issuance of 182,335 new shares (approx. 0.8% of the share capital) to former contributing shareholders of Medigene Immunotherapies GmbH (formerly: Trianta Immunotherapies GmbH).

As announced on 10 July 2017, the milestone was achieved by filing the clinical trial authorization application (CTA) for Medigene's Phase I/II clinical trial of its TCR therapy MDG1011. The milestone payment was a part of the purchase price agreed for the acquisition of Trianta in January 2014. With this third and final milestone payment, the total purchase price of approx. EUR 10 million will have been entirely settled.

The number of these new shares was calculated, according to the acquisition agreement, on the basis of the volume-weighted average price (VWAP) of Medigene shares in the 30-day period prior to and the 30-day period from 10 July 2017 being the date on which the achievement of the milestone was announced. The calculated VWAP is approx. EUR 10.97. The new shares will be tradeable at the German Stock Exchange following their registration at the commercial register, however, the subscribers of the new shares agreed to a lockup period of 14 months.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

(Ende)

Aussender: Medigene AG
Lochhamer Straße 11
82152 Planegg
Deutschland
Ansprechpartner: Julia Hofmann, Head of Public and Investor Relations
Tel.: +49 89 200033-3301
E-Mail:
Website: www.medigene.de
ISIN(s): DE000A1X3W00 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Medigene AG